摘要
目的观察紫杉醇联合顺铂、氟尿嘧啶诱导化疗加同步放化疗治疗晚期鼻咽癌的临床疗效及安全性。方法将62例晚期鼻咽癌患者随机分为观察组(31例)和对照组(31例),观察组采用紫杉醇联合顺铂、氟尿嘧啶诱导化疗2个周期,诱导化疗结束14d后,再进行顺铂同步放化疗。对照组单纯采用顺铂同步放化疗,观察比较两组的临床疗效和不良反应。结果观察组的总有效率为96.8%(30/31),明显高于对照组的74.2%(23/31),差异有统计学意义(P<0.05)。对照组的消化道反应及口腔溃疡发生率分别为54.8%(17/31)和48.4%(15/31),均低于观察组的80.6%(25/31)和74.2%(23/31)(P<0.05)。两组骨髓抑制差异无统计学意义[51.6%(16/31)比54.8%(17/31)](P>0.05)。结论紫杉醇联合顺铂、氟尿嘧啶诱导化疗加同步放化疗治疗晚期鼻咽癌的近期疗效较好,不良反应可以耐受,远期疗效有待于进一步观察。
Objective To evaluate the efficacy of paclitaxel and cisplatin.fluorouracil induction chemotherapy plus concurrent chemoradiotherapy in treatment of advanced nasopharyngeal carcinoma. Methods Total fifty-six patients with advanced nasopharyngeal carcinoma were randomized into the observation group （ n = 31 ） and the control group （ n = 31 ）. The observation group treated with 2 cycles of induCtion chemotherapy with paclitaxel and cisplatin,fluorouracil followed by 3 cycles of cisplatin and radiotherapy. The control group treated with cisplatin concurrent chemotherapy and radiotherapy. The clinical effect and adverse reaction were compared between two groups. Results The total effective rate in observation group was 96. 8% （30/31 ） ,which significandy higher than that in control group [ 74. 2% （ 23/31 ） ] （ P 〈 0. 05 ）. The rate of gastrointestinal reactions and oral ulcers in observation group were 54. 8% （ 17/31 ） and 48.4% （ 15/31 ） ,which significantly lower than those in control group [ 80. 6% （25/31 ） ,74. 2% （23/31 ） ] （P 〈 0. 05 ）. The rate of bone marrow suppression between two groups had no significant difference [51.6% （16/31）vs. 54. 8% （17/31） ] （P 〉0. 05）. Conclusion Paelitaxel and eisplatin, fluorouracil induction chemotherapy plus concurrent chemoradiotherapy is effective and tolerable in the treatment of advanced nasopharyngeal carcinoma. Long-term therapeutic effects of this treatment need further observation.
出处
《中国实用医药》
2013年第11期11-13,共3页
China Practical Medicine
关键词
鼻咽癌
诱导化疗
紫杉醇
顺铂
氟尿嘧啶
同步放化疗
Nasopharyngeal carcinoma
Induction chemotherapy
Paclitaxel
Cisplatin
Fluorouraeil
Concurrent chemoradiotherapy
